Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Januar 2009 10:35 ET | Quelle: Bioheart, Inc.

Bioheart Announces Commercial Order for TGI 1200(tm) Adult Stem Cell Isolation System for Use in Chronic Limb Ischemia Patients

SUNRISE, Fla., Jan. 14, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT) announced today it has received a purchase order for a TGI 1200 System from Philadelphia BioMed Product Development...
14. Januar 2009 09:30 ET | Quelle: Merit Medical Systems, Inc.

Merit Medical Announces Microcatheter Market Entry

SOUTH JORDAN, Utah, Jan. 14, 2009 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology and...
13. Januar 2009 12:10 ET | Quelle: Nymox Pharmaceutical Corporation

Nymox Releases Positive New Clinical Trial Data On Durability of Response Rates to Company's BPH Drug NX-1207

HASBROUCK HEIGHTS, N.J., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the release of positive new clinical trial data from the Company's most recent...
13. Januar 2009 10:42 ET | Quelle: Bioheart, Inc.

Bioheart Files for Reimbursement Approval in Switzerland for MyoCell(r) Myogenic Stem Cell Therapy for Heart Failure

SUNRISE, Fla., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT) announced today it has filed with appropriate agencies in Switzerland for reimbursement approval for its MyoCell(r)...
13. Januar 2009 08:46 ET | Quelle: Canon Medical Informatics, Inc

Vital Images and Toshiba Sign Co-development Agreement

MINNEAPOLIS, Jan. 13, 2009 (GLOBE NEWSWIRE) -- Vital Images, Inc. (Nasdaq:VTAL), a leading provider of advanced visualization and analysis software, and Toshiba Medical Systems Corporation (Toshiba),...
13. Januar 2009 07:30 ET | Quelle: Talon Therapeutics, Inc.

Hana Biosciences Phase 1 Data On Menadione, Its Novel First-in-Class Compound for Treatment-Limiting Skin Toxicity Associated With EGFR Inhibitors, to be Presented At 33rd Hawaii Dermatology Seminar

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced an...
12. Januar 2009 09:30 ET | Quelle: Generex Biotechnology Corp.

Generex Biotechnology Announces Publication of Novel Immunotherapeutic Cancer Vaccine Studies

WORCESTER, Mass., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today the publication of a report reviewing the studies performed to...
12. Januar 2009 09:00 ET | Quelle: BiPar Sciences

BiPar Sciences Raises $20 Million to Advance Clinical Programs

BRISBANE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today it has raised...
12. Januar 2009 06:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Initiates Phase 2 Clinical Trial of LX1031 in Patients With Irritable Bowel Syndrome

THE WOODLANDS, Texas, Jan. 12, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human...
12. Januar 2009 06:00 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Announces 2009 and Long-Term Goals, Building On 2008 Success

Begins 2009 With Four Years of Capital, Three Clinical Candidates in Development, Two New INDs, and One Pivotal Trial Introduces "I4 2012" Long-Term Goals CAMBRIDGE,...

Vorherige Seite

Nächste Seite